查詢結果分析
來源資料
相關文獻
- 異體周邊造血先期細胞移植之現況及未來展望
- 海洋性貧血患童ABO 血型不合之異體骨髓移植
- Graft Versus Host Disease in Allogeneic Bone Marrow Transplantation
- Cyclosporine-Induced Encephalopathy in a Patient with Relapsed Acute Myeloid Leukemia Treated with Unrelated Allogeneic Bone Marrow Transplantation
- Bone Marrow Transplantation from an HLA-Matched Unrelated Donor for Treatment of Chediak-Higashi Syndrome
- Allogeneic Bone Marrow Transplantation for Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Childhood
- 輸血相關性移植物抗宿主病與血液成分的照光作業
- 異體骨髓移植治療白血病進展
- 異體骨髓移植技術之介紹
- 異體骨髓移植的相關併發症
頁籤選單縮合
題名 | 異體周邊造血先期細胞移植之現況及未來展望=Allogeneic Peripheral Blood Progenitor Cells Transplantation: Current Status and Future Prospect |
---|---|
作者 | 黃聖懿; 唐季祿; 陳耀昌; | 書刊名 | 內科學誌 |
卷期 | 9:1 1998.03[民87.03] |
頁次 | 頁28-35 |
分類號 | 415.635 |
關鍵詞 | 周邊造血先期細胞; 異體骨髓移植; 白血球生長因子; 白血球濾過術; Peripheral blood progenitor cells; Allogeneic bone marrow transplantation; Leukocyte growth factor; Leukapheresis; |
語文 | 中文(Chinese) |
中文摘要 | 異體周邊造血先期細胞移植(allogeneic peripheral blood progenitor cells transplantahon)便是利用白血球生長因子(leukocyte growth factors)動員(mobilize) 捐贈者骨髓�堛熙y血先期細胞至周邊血液中,並加以收集,然後輸注至受捐者的體內以重 建其造血機能。此種方法如同一般異能骨髓移植(allogeneic bone marrow trmsplmtation),對許多血液惡性疾病、先天或後天造血機能異常者,如白血病( leukemia)、淋巴瘤(lymphoma)、地中海型貧血(thalassemia)及再生不足性貧血( aplastic anemia)等皆有治癒的效果。唯有不同處是前者不若後者需冒手術及全身麻醉的 危險,而只要如捐血般將周邊血液中的造血先期細胞捐出即可,實謂一種較安全且簡便的 收集方法。經近三年來歐美臨床研究顯示,其相較於傳統異體骨髓移植,不但安全性較高 而且受捐者恢復較快,平均只要14天即可重建造血系統,這使得住院天數減少並且可以降 低成本。另外,其治療成效亦相當。但前者是由周邊血液收集,擁有較多的T-細胞及自然 殺手細胞(natural killer cells),因此可能有較為優異的植體抗白血病效果(graft- versus-leukemia effect; GvL),然而急性植體抗宿主疾病(acute graft-versus-host disease;aGvHD)的比例卻並未隨之昇高。由於# 330 1$a此法好處甚多,所以未來這種異 體周邊造血先期細胞移植可能會逐漸取代異體骨髓移植而成為此一治療的主流。 Allogeneic peripheral blood progenitor cells transplantation (PBPCT) is a recent treatment modality which collects and preserves hematopoietic progenitor cells derived from normal donors in peripheral blood after mobilization by some leukocyte growth factors such as granulocyte or granulocyte- macrophage colony-stimulating factor (G-CSF or GM-CSF) and transfuses to recipients, as allografts, to reconstitute their hematopoietic systems. As compared with traditional allogeneic bone marrow transplantation (BMT), it is an alternative way to obtain blood progenitor cells from different resources and can be applied to accompanied with high-dose chemotherapy in order to cure hematology malignancies, hereditary and acquired hematopoietic disorders, such as leukemia, lymphoma, thalassemia and aplastic anemia. General anesthesia and bone marrow punctures and hospitalization of the donor become unnecessary while this technique is used. In the recipient side, it may have more remarkable advantages over bone marrow in allowing more rapid engraftment, earlier discharge from hospital and decreased costs. Theoretically, enhanced graft-versus-leukemia effect may also be expected from the presence of larger numbers of T- lymphocytes and natural killer cells in the graft and hence a beneficial effect on the relapse risk post-transplant. Interestingly, the incidence and severity of acute graft-versus-host disease (GVHD) appear to be not significantly different, although chronic GVHD might be increased when compared with allogeneic BMT. Long term effect of G-CSF on donor is not well- known. However, there was not report of leukemia in donor with accumulated experience of 10 years. It is speculated that allogeneic PBPCT may replace allogeneic BMT as the main treatment modality in the future to reconstitute hematopoiesis after myeloablative therapy.(J Intern Med Taiwan 1998 9 : 28- 35) |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。